# AI accelerates development of thermostable mRNA vaccines Bayesian optimization enables cold-chain-free delivery via microneedle patches - **Source:** [Nature Biotechnology](http://feeds.nature.com/nbt/rss/current) - **Published:** 2026-09-28 - **Original article:** - **On Brifing:** https://brifing.si/s/40ed7c84-3229-4399-9f90-343cf08251c2 ## AI-driven vaccine stabilization The AGENT framework combines high-throughput experimentation with Bayesian optimization to rapidly engineer thermostable mRNA vaccines. These solid-state formulations maintained full bioactivity after two months at 37°C, matching fresh vaccine performance. The approach specifically addresses the thermal instability that has limited mRNA vaccine distribution in resource-constrained settings. ## Cold-chain breakthrough Successful animal trials demonstrated vaccine delivery via microneedle patches without refrigeration requirements. This eliminates the need for temperature-controlled supply chains that currently constrain global vaccine access. The technology proved equally effective in both rodents and nonhuman primates, suggesting scalable human application. ## Bayesian optimization advantage The AI system efficiently navigates complex parameter spaces to identify optimal mRNA-lipid nanoparticle formulations. This data-efficient approach accelerates development compared to traditional trial-and-error methods. The framework builds on established Bayesian optimization techniques previously applied in other engineering domains. ## Comparative performance The thermostable vaccines elicited immune responses equivalent to conventional refrigerated formulations. Testing confirmed no loss of potency after extended high-temperature storage. This performance parity addresses a critical barrier for mRNA vaccine deployment in tropical climates. ## Microneedle delivery system The patch-based administration method complements the thermostable formulation. This combination enables complete cold-chain independence from manufacture through administration. Recent studies with clinically relevant LNP compositions support the translational potential of this approach. ## Resource-constrained applications The technology specifically targets challenges in low-resource settings where refrigeration infrastructure is limited. Successful implementation could dramatically improve vaccine accessibility in developing regions. The approach aligns with global health priorities for outbreak-responsive vaccine deployment. ## Technical validation The study builds on prior work demonstrating microneedle delivery of COVID-19 mRNA vaccines. Researchers validated the system using established nanoparticle compositions to ensure clinical relevance. Multiple animal models confirmed the reproducibility of results across species. ## Future implications This AI-accelerated platform could transform vaccine development timelines for emerging pathogens. The thermostable format enables stockpiling for pandemic preparedness. The technology's modular nature suggests applicability beyond current mRNA vaccine targets. ## Sources covering this story - https://www.nature.com/articles/s41587-026-03330-x — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._